In this respect, metformin, despite raising hepatic sensitivity to insulin and reducing steatosis in a cohort of NAFLD individuals [302] reached eventually insufficient results in a large meta-analysis [303]. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.